Clinical Management of Recurrent Retinopathy of Prematurity after Intravitreal Bevacizumab Monotherapy.

ABSTRACT:

Purpose

To determine incidence, risk factors, risk period, and characteristics of recurrent retinopathy of prematurity (ROP) treated by intravitreal bevacizumab (IVB) monotherapy.

Design

Retrospective case series.

Participants

Premature infants with type 1 ROP (subdivided into stage 3+ ROP and aggressive posterior ROP [APROP]) in zone I or zone II posterior who received IVB monotherapy and were followed up for at least 65 weeks adjusted age (AA).

Methods

Retrospective review of infants who demonstrated recurrence of type 1 ROP after IVB monotherapy, including examination of RetCam fundus photographs and fluorescein angiograms.

Main outcomes measures

Incidence, risk factors, risk period, and characteristics of recurrent ROP.

Results

Intravitreal be

SUBMITTER: Mintz-Hittner HA 

PROVIDER: S-EPMC4995132 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature